Allergen immunotherapy in a patient with human immunodeficiency virus: Effect on T-cell activation and viral replication

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 5, 2007, Pages 495-497

  Randhawa, Inderpal Singh ^a   Junaid, Imran ^a   Klaustermeyer, William B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR;

ADULT; ALLERGIC RHINITIS; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VACCINATION REACTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 34248576472     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60767-3     Document Type: Article

References (11)

1. Marshall GD Jr. AIDS, HIV-positive patients, and allergies. Allergy Asthma Proc. 1999;20:301-304.
2. Ramilo O, Hicks PJ, Borvak J, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J. 1996;15:197-203.
3. Keller M, Deveikis A, Cutillar-Garcia M, et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J. 2000;19:613-618.
4. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997;11:1013-1021.
5. Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2004;53:1-40.
6. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of three randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000;182:428-434.
7. + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial. J Infect Dis. 2000;181:1148-1152.
8. Skowron G, Stein D, Drusano G, et al. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial. J Infect Dis. 1999;180:1064-1071.
9. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med. 1995;182:1067-1077.
10. Nugeyre MT, Monceaux V, Beq S, et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol. 2003;171:4447-4453.
11. + T cell proliferation in HIV infection. J Med Virol. 2006;78:1147-1157.